St. John's Wort
St. John's Wort induces CYP3A4, reducing diltiazem plasma levels significantly. This can lead to uncontrolled hypertension or angina.
Recommendation: Avoid combining St. John's Wort with diltiazem.
Prescription ·Strong evidence ·Reviewed May 2026
Diltiazem is a benzothiazepine-type non-dihydropyridine calcium channel blocker that affects both vascular smooth muscle and cardiac conduction tissue. It is used for hypertension, angina, and rate control in atrial fibrillation/flutter. Its dual action on vessels and the AV node makes it versatile.
The bottom line
Evidence rating strong. Most-documented uses: effective blood pressure reduction, rate control in atrial fibrillation/flutter, angina relief including vasospastic (prinzmetal) angina. 10 sources indexed (2018–2024), with 8 interaction records on file.
Core mechanism
Inhibits L-type calcium channels in both vascular smooth muscle and cardiac tissue. Causes vasodilation (reducing blood pressure), slows conduction through the AV node (rate control), and reduces myocardial contractility and oxygen demand. Also has coronary vasodilatory properties, making it effective for vasospastic angina.6,7
Extended-release formulations can be taken with or without food; immediate-release absorption is not significantly affected by food
St. John's Wort induces CYP3A4, reducing diltiazem plasma levels significantly. This can lead to uncontrolled hypertension or angina.
Recommendation: Avoid combining St. John's Wort with diltiazem.
Diltiazem is itself a moderate CYP3A4 inhibitor that depends on the same enzyme for clearance. Adding berberine, which inhibits CYP3A4, CYP2D6, and CYP2C9 in humans, can raise diltiazem levels and amplify its negative chronotropic and vasodilatory effects. The result can be excessive bradycardia, hypotension, or AV block, particularly in older adults or those on other rate-slowing drugs.
Recommendation: Avoid combining berberine with diltiazem unless your prescriber agrees. If used together, check your pulse and blood pressure twice daily for 2 weeks after starting berberine and report a resting heart rate below 50 bpm, lightheadedness, or readings below your usual range.
Resveratrol is a mechanism-based inhibitor of CYP3A4 and a P-glycoprotein blocker. In rats, oral resveratrol increased diltiazem AUC and Cmax 1.5-fold by inhibiting both intestinal CYP3A and efflux transport. The extrapolated human effect would amplify diltiazem's bradycardia and hypotension, particularly when patients use high-dose resveratrol supplements (250-1000 mg/day).
Recommendation: Avoid high-dose resveratrol supplements while on diltiazem. If you do use resveratrol, separate doses by at least 4 hours, check pulse and blood pressure for 2 weeks, and reduce or stop the supplement if your HR drops below 50 bpm or you become lightheaded.
Quercetin pretreatment in rabbits roughly doubled the oral bioavailability of diltiazem by inhibiting CYP3A4 and intestinal P-glycoprotein. While human data are limited, large-dose quercetin supplements (500-1000 mg/day) are plausibly able to raise diltiazem levels and accentuate bradycardia, hypotension, or AV-nodal blockade.
Recommendation: Avoid high-dose quercetin supplements while on diltiazem. If you use quercetin, keep doses modest (under 500 mg/day), separate from diltiazem by at least 4 hours, and monitor pulse and blood pressure for 2 weeks.
L-Theanine modestly lowers stress-induced blood pressure increases and has mild relaxing effects on vascular tone. Layered on top of diltiazem's bradycardia, vasodilation, and negative inotropy, the combination can produce additive drops in heart rate or blood pressure, particularly in patients who are already well-controlled or volume-depleted.
Recommendation: If you take diltiazem, L-theanine doses up to 200-350 mg/day supplemental elemental magnesium are usually well-tolerated, but check your blood pressure and pulse when you start. Reduce or stop the supplement if you develop dizziness, fatigue, or a resting heart rate below 50 bpm.
Taurine produces small but consistent reductions in blood pressure (about 3-4 mmHg systolic in meta-analysis) and slows heart rate through autonomic modulation. Added to diltiazem's negative chronotropic and vasodilatory effects, the combination can produce additive bradycardia or hypotension, particularly in older patients or those on additional rate-slowing medications.
Recommendation: If you take diltiazem, taurine doses up to 1.5-3 g/day are usually tolerable, but check blood pressure and pulse when you start. Hold or reduce taurine if your HR drops below 50 bpm or you develop new dizziness or fatigue.
Magnesium is a physiologic calcium antagonist that lowers blood pressure by about 2/1.8 mmHg at supplemental doses and also blunts sinoatrial and AV-nodal conduction. Combined with diltiazem's rate-slowing and vasodilatory effects, the result can be additive bradycardia, hypotension, or AV-nodal slowing, particularly with high magnesium doses or IV use.
Recommendation: If you take diltiazem, keep oral magnesium citrate to 200-350 mg/day supplemental elemental magnesium and monitor blood pressure and pulse after starting. Reduce or stop magnesium if your HR drops below 50 bpm, you develop dizziness, or your BP falls below your usual range. Avoid IV magnesium without specialist supervision.
Aged garlic extract reduces systolic and diastolic blood pressure by about 8 and 5 mmHg in hypertensive patients. Combined with diltiazem's vasodilatory and rate-slowing effects, the additive antihypertensive response can be welcome but also risks symptomatic hypotension or dizziness, especially in older patients or those at goal blood pressure.
Recommendation: If you take diltiazem, monitor blood pressure and pulse for 2-4 weeks after starting garlic extract. Reduce or stop garlic if readings drop below your usual range, you become dizzy, or your heart rate falls below 50 bpm.
Numbered references. Citations throughout the page link here.
Bolton A, Paudel B, Adhaduk M et al.. Intravenous Diltiazem Versus Metoprolol in Acute Rate Control of Atrial Fibrillation/Flutter and Rapid Ventricular Response: A Meta-Analysis of Randomized and Observational Studies. American journal of cardiovascular drugs : drugs, devices, and other interventions. 2024
Mayow AH, Sinha T, Ahmad M et al.. Comparison of the Effectiveness and Safety of Metoprolol and Diltiazem in Atrial Fibrillation With Rapid Ventricular Rate Patients: A Systematic Review and Meta-Analysis. Cureus. 2024
Jaya F, Afzal M, Anusha F et al.. Efficacy and Safety of Intravenous Diltiazem Versus Metoprolol in the Management of Atrial Fibrillation with Rapid Ventricular Response in the Emergency Department: A Comprehensive Umbrella Review of Systematic Reviews and Meta-analyses. The Journal of innovations in cardiac rhythm management. 2024
Sharda SC, Bhatia MS. Comparison of diltiazem and metoprolol for atrial fibrillation with rapid ventricular rate: Systematic review and meta-analysis. Indian heart journal. 2022
Hu Y, Yang X, Zhang L et al.. Perioperative diltiazem or nitroglycerin in on-pump coronary artery bypass: A systematic review and network meta-analysis. PloS one. 2018
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.